BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12874391)

  • 21. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.
    Claassen J; Teufel J; Kalla R; Spiegel R; Strupp M
    J Neurol; 2013 Feb; 260(2):668-9. PubMed ID: 23183922
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical treatment of acquired nystagmus.
    Ehrhardt D; Eggenberger E
    Curr Opin Ophthalmol; 2012 Nov; 23(6):510-6. PubMed ID: 23014266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
    Kalla R; Teufel J; Feil K; Muth C; Strupp M
    J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling drug modulation of nystagmus.
    Glasauer S; Rössert C
    Prog Brain Res; 2008; 171():527-34. PubMed ID: 18718349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transition from downbeat to upbeat nystagmus caused by 4-aminopyridine.
    Feil K; Claaßen J; Bardins S; Teufel J; Habs M; Kalla R; Strupp M
    J Neurol; 2013 May; 260(5):1426-8. PubMed ID: 23595790
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of 4-aminopyridine on gravity dependence and neural integrator function in patients with idiopathic downbeat nystagmus.
    Sander T; Sprenger A; Marti S; Naumann T; Straumann D; Helmchen C
    J Neurol; 2011 Apr; 258(4):618-22. PubMed ID: 21057959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
    Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
    Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
    [No Abstract]   [Full Text] [Related]  

  • 28. Amifampridine phosphate in congenital myasthenic syndrome.
    Verma S; Mazell SN; Shah DA
    Muscle Nerve; 2016 Oct; 54(4):809-10. PubMed ID: 27348204
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
    Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
    Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dalfampridine in patients with downbeat nystagmus--an observational study.
    Claassen J; Feil K; Bardins S; Teufel J; Spiegel R; Kalla R; Schneider E; Jahn K; Schniepp R; Strupp M
    J Neurol; 2013 Aug; 260(8):1992-6. PubMed ID: 23589193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aminopyridines for the treatment of cerebellar and ocular motor disorders.
    Strupp M; Kalla R; Glasauer S; Wagner J; Hüfner K; Jahn K; Brandt T
    Prog Brain Res; 2008; 171():535-41. PubMed ID: 18718350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The origin of downbeat nystagmus: an asymmetry in the distribution of on-directions of vertical gaze-velocity Purkinje cells.
    Marti S; Straumann D; Glasauer S
    Ann N Y Acad Sci; 2005 Apr; 1039():548-53. PubMed ID: 15827020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
    Feil K; Bremova T; Muth C; Schniepp R; Teufel J; Strupp M
    Cerebellum; 2016 Feb; 15(1):38-42. PubMed ID: 26519380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
    Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
    Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus.
    Dieterich M; Straube A; Brandt T; Paulus W; Büttner U
    J Neurol Neurosurg Psychiatry; 1991 Jul; 54(7):627-32. PubMed ID: 1654396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological advances in the treatment of neuro-otological and eye movement disorders.
    Strupp M; Brandt T
    Curr Opin Neurol; 2006 Feb; 19(1):33-40. PubMed ID: 16415675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nystagmus: an update on treatment in adults.
    Straube A
    Expert Opin Pharmacother; 2005 Apr; 6(4):583-90. PubMed ID: 15934884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does 4-aminopyridine "beat" downbeat nystagmus?
    Shaikh AG
    J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1298-9. PubMed ID: 23833267
    [No Abstract]   [Full Text] [Related]  

  • 39. Vertical vestibular responses to head impulses are symmetric in downbeat nystagmus.
    Glasauer S; von Lindeiner H; Siebold C; Büttner U
    Neurology; 2004 Aug; 63(4):621-5. PubMed ID: 15326232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of aminopyridines in neurological disorders.
    Sedehizadeh S; Keogh M; Maddison P
    Clin Neuropharmacol; 2012; 35(4):191-200. PubMed ID: 22805230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.